Showing posts with label Patents. Show all posts
Showing posts with label Patents. Show all posts

Friday, December 12, 2014

The 'Mi' Trouble

The world of smartphones has witnessed constant growth and has become the subject of numerous infringement suits. Xiaomi is no stranger to controversies. As soon as the electronics firm entered the Indian Smartphone market, a few months down the line, has been blocked from selling handsets. 

At the crux of the matter, lies the infringement claims of eight registered Standard Essential Patents of Ericsson. The Hon'ble Delhi High Court has passed an injunction forbidding the firm from producing, building, importing or selling smartphones utilizing the Patent in India. India being its largest market outside China, this surely has come off as a blow to the infant company.

Xiaomi and Flipkart, e-commerce partner, have to announce how many devices have been shipped, so as to calculate the compensation due to Ericsson. In an earlier infringement suit against Micromax, Ericsson is to receive 1% of the selling price of the devices, by way of royalty, for use of latter's Standard Essential Patents. 

While thee court has directed the Central Board of Excise and Customs to stop the import of devices from Xiaomi, it is to be looked how the firm's legal team works a way out of this suit. 

- Bagmisikha Puhan




Wednesday, November 27, 2013

Google Tattoo



For years tattoos have been a fashion statement, but in future tattoos can me much more than that. Google owned Motorola Mobility has recently filed a patent in USPTO for an electronic neck tattoo that can serve as a lie detector. The tattoo can be pasted on the neck or worn on collar or on a band around the user’s neck. The patent application highlights that “the electronic skin tattoo can include a galvanic skin response detector to detect skin resistance of a user; it is contemplated that a user may be nervous or engaging in speaking falsehoods may exhibit different galvanic skin response than a more confident, truth telling individual.”

The tattoo can mainly serve as supplementary microphone and can be paired with various electronic devices such as smartphones, tablets etc.  This means that the user can easilycommunicate through mobile phone by a voice command without having to press any button. The tattoo can run on rechargeable batteries or can usesolar panel technology, capacitive technology, nanotechnology or electro-mechanical technology as explained in the patent application.

 

Picture: A drawing from patent application of Google’s neck tattoo by Motorola

The patent which is titled "Coupling an Electronic Skin Tattoo to a Mobile Communication Device” is primarily meant for nullifying the background noise when a caller speaks from a crowded surrounding. The tattoo worn on the neck can improve the voice quality by making the caller more audible to the person on the other end of the call through a noise-cancelling system.

Interestingly, the tattoo could also be worn by animals, although we are clueless as to how it could help an animal. But for now we are sure that this new wearable technology will make one think before lying.

Authored by Sai Ratna Manjari

Posted By Aurobinda Panda

For Biswajit Sarkar – Advocates – IP Attorney

Monday, August 12, 2013

Roche loses Herceptin Patent


After the landmark grant of Compulsory license (CL) for Bayer’s Nexavar to Natco last year, a trend of CL application seems to have started in India. Recently, health ministry has recommended CL for a breast cancer drug Trastuzumab after various campaigns held regarding the affordability of this expensive drug in India. However, Department of Industrial Policy and Promotion (DIPP) has refused the CL for Trastuzumab (Herceptin) manufactured by Swiss multinational Roche.

It was previously reportedthat the health ministry has suggestedrevoking the patent in public interest under section 66 of Indian patent act 1970. However, a recent clarification from Kolkata patent office suggests that the three patents for Herceptin were not revoked but were abandoned or withdrawn because Roche failed to file the documents before deadline and did not appear for the hearing concerning its Herceptin patent.Although, Roche did not make any comments regarding the lapse of its patent; the Herceptin patent IN205534 is diminishing due to its post-grant opposition. India awarded patent for Roche’s Herceptin in 2007 which is currently extended till 2019. Three more patents related to the original patents were further filed, but were withdrawn since Roche failed to meet the deadline. The request for examination of one of the patents was not filed before deadline, while the same was filed for other two after the patent grant, which is not permitted in Indian patent law. Herceptin is said to be the third biggest seller by Roche.

Although, the Herceptin patent is abandoned, the generic version of this drug may not come to the market anytime soon. Currently, Roche’s Herceptin sells for Rs.1,34,000 per vial but Roche also sells the cut price version of this drug through an Indian generic company Emcure Pharmaceuticals Ltd. at the cost of Rs.70,000 per vial. Any generic version of this drug in Indian markets will lead to patent infringement. Besides, this drug is a Biotech drug and developing such a drug under generic company set up is not easy.





There are speculations that CL was refused by DIPP after widespread criticism from International community on CL to Nexavar. In the recent times, Indian IP office has been serious about the submission of ‘statement of working’ or form 27 by the companies regarding their working of patents in India. However, last year for the first time this information from various companies has been made available to public. Although the reason behind the disclosure of such confidential information is not known but it is wondered that lack of such information by the company regarding the working of the patent in India or information on non-working of patent may favour companies seeking CL. On one hand,with government enabling affordability of lifesaving drug to patients and on the other hand critics pointing fingers at Indian IP laws, only time will where India’s healthcare is heading.

Authored by Sai Ratna Manjari

Posted By Aurobinda Panda

For Biswajit Sarkar – Advocates – IP Attorney

Monday, October 8, 2012

Patent in USA

This post is a case comment on the much-awaited decision Mayo v Prometheus. Main question posed before the Supreme Court was "Whether the claims of Prometheus preempt patent law?" The Court, in my view delivered a promising judgment disallowing the patenting of natural laws. Personal life science invention is a growing market in US. It is likely that following days will show the positive or negative repercussions of the decision. However, a lime light for Justice Breyer, who had been a minority in similar cases, found his war against monopolizing freethinking.

The United States Supreme Court on 20 March decided unanimously that patent of Prometheus claiming methods to administer thiopurine drugs to treat autoimmune diseases is void.

Prometheus was the sole licensor of thiopurine drug “When in­gested, the body metabolizes the drugs, producing metabolites in the bloodstream. Because patients metabolize these drugs differently, doctors have found it difficult to determine whether a particular pa­tient’s dose is too high, risking harmful side effects, or too low, and so likely ineffective. The patent claims here set forth processes embody­ing researchers’ findings that identify correlations between metabo­lite levels and likely harm or ineffectiveness with precision. Each claim recites (1) an “administering” step—instructing a doctor to ad­minister the drug to his patient—(2) a “determining” step—tellingthe doctor to measure the resulting metabolite levels in the patient’s blood—and (3) a “wherein” step—describing the metabolite concen­trations above which there is a likelihood of harmful side-effects and below which it is likely that the drug dosage is ineffective, and in­forming the doctor that metabolite concentrations above or below these thresholds “indicate a need” to decrease or increase (respective­ly) the drug dosage.”

Petitioners Mayo introduced their own method, which according to Prometheus violated their patent claims. The district court held that patent claims constituted principles of natural law, which preempts the patent law. Federal Circuit Court overturned the decision based on Machine or transformation test held in Bilski v Kappos. Now the Supreme Court of the United States has affirmed the decision of district court and held that patent claims are void.

The Court held that, “The “wherein” clauses simply tell a doctor about the relevant natural laws, adding, at most, a suggestion that they should consider the test results when making their treatment decisions. The “determining “step tells a doctor to measure patients’ metabolite levels, through whatever process the doctor wishes to use. Because methods for making such determinations were well known in the art, this step simply tells doctors to engage in well-understood, routine, conven­tional activity previously engaged in by scientists in the field. Such activity is normally not sufficient to transform an unpatentable law of nature into a patent-eligible application of such a law.”

Section 101 of US Patent Act has an explicit exemption that “Laws of nature are not patentable.” The same idea was followed in various celebrated precedence like  Funk Brothers Seed Co. v. Kalo Inoculant Co., 333 U. S. 127, 130 (1948), Dia­mond v. Diehr, 450 U. S. 175, 185 (1981); Bilski v. Kappos, 561 U. S (2010); Diamond v. Chakrabarty, 447 U. S. 303, 309 (1980); Le Roy v. Tat­ham, 14 How. 156, 175 (1853); O’Reilly v. Morse, 15 How. 62, 112–120 (1854). 

The Court in Chakrabarty held that patentable subject matter includes anything under the sun that is made by man. “Made by man” is an important criterion for patentability because the cardinal patent eligibility criterion for a “principle of natural law” is that it must undergone substantial human intervention. The decision in Diehr is in direct relation to the facts of the case. In Diehr the claimed invention was a known mathematical formula, the Arrhenius equation, applied to identify the time to open a rubber press. The invention worked on the information about the temperature inside the mold, the time in which the rubber was inside the mold and thickness of the rubber. However, the court identified that invention as a whole had undergone substantial human intervention and hence patent eligible. To quote “installing rubber in a press, closing the mold, constantly determining the temperature of the mold, constantly re- calculating the appropriate cure time through the use of the formula and a digital computer, and automatically opening the press at the proper time” (at p.187 of Diehr).

In the present case, court identified that the claims only reinstating a process of natural law and there is no substantial human intervention to make the invention patentable.

By Aurobinda Panda